[go: up one dir, main page]

WO2008062453B1 - Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form - Google Patents

Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form

Info

Publication number
WO2008062453B1
WO2008062453B1 PCT/IN2007/000439 IN2007000439W WO2008062453B1 WO 2008062453 B1 WO2008062453 B1 WO 2008062453B1 IN 2007000439 W IN2007000439 W IN 2007000439W WO 2008062453 B1 WO2008062453 B1 WO 2008062453B1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
salicylate
nicotine base
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2007/000439
Other languages
French (fr)
Other versions
WO2008062453A2 (en
WO2008062453A3 (en
Inventor
Nikki Nikhilesh Singh
Umesh Shantisingh Tomar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008062453A2 publication Critical patent/WO2008062453A2/en
Publication of WO2008062453A3 publication Critical patent/WO2008062453A3/en
Publication of WO2008062453B1 publication Critical patent/WO2008062453B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition comprising 1-99weight % nicotine base and 1-99wt% C. sub. 1-C. sub.5 alkyl salicylate (preferably methylsalicylate ) for use in the treatment of disorders of addiction and smoking in particular characterized in that nicotine base is released in vapor form.

Claims

AMENDED CLAIMS received by the International Bureau on 04 September 2008
1. A method of safe and effective treatment of disorders of addiction in general and smoking in particular by administering to a human or animal in need of the treatment a therapeutically-effective amount of a dosage form of nicotine base in vapor form released from a composition comprising: (i) 1% to 99% by weight of nicotine base; (ii) 1% to about 99% by weight of C1-C5 alkyl salicylate; and any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI; antitussives, such as dextromethorphan; antihistamines, such as chlorpheniramine maleate; analgesics, such as acetaminophen; or antibacterials, such as cetyl pyridinium chloride and other ingredients and excipients required for effective delivery of the dosage form.
2. A method of safe and effective treatment of disorders of addiction in general and smoking in particular by administering to a human or animal in need of the treatment a therapeutically-effective amount of a dosage form of nicotine base in vapor form released from a composition as claimed in claim 1 comprising: (i) 1% to 99% by weight of nicotine base; (ii) 1% to about 99% by weight of C1-C5 alkyl salicylate; and any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI (60mg); antitussives, such as dextromethorphan (20mg); antihistamines, such as chlorpheniramine maleate (24gm); analgesics, such as acetaminophen (lOOOmg); or antibacterials, such as cetyl pyridinium chloride (0.05 by weight of the composition) and other ingredients and excipients required for effective delivery of the dosage form.
3. A method of treatment according to claim 1 is for treatment of addiction to smoking and tobacco.
4. A method of treatment according to claim 1 wherein the nicotine base in vapor form is preferably nasally or orally inhaled and is released in vapor form from a composition preferably comprising: (i) 0.5% to 25% by weight of nicotine base;
(ii) 1% to 75% by weight of C1-C5 alkyl salicylate; and any one of the pharmaceutical agents listed below: pseudonicotine HCI (60mg); dextromethorphan (20mg); chlorpheniramine maleate (24gm); acetaminophen (lOOOmg); or cetyl pyridinium chloride (0.05 by weight of the composition) and other ingredients and excipients required for effective delivery of the dosage form.
5. A method of treatment according to claim 3 comprising 5% to 10% by weight of nicotine base and 5% to 25% by weight of alkyl salicylate.
6. A method of treatment according to claim 1 wherein the composition further comprises 2% to 93% by weight aromatic compounds.
7. A method of treatment according to claim 3 wherein the amount of nicotine base delivered by nasal or oral treatment is from 1 microgram to 10 micrograms per day if inhaled or ingested one to several times as per need.
8. A method of treatment according to claim 3 wherein the alkyl salicylate is methyl salicylate.
9. A composition for safe and effective treatment of disorders of addiction in general and smoking in particular by administering to a human or animal in need of the treatment comprising:
(i) 1% to 99% by weight of nicotine base; (ii) 1% to about 99% by weight of Ci-C5 alkyl salicylate; and any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI; antitussives, such as dextromethorphan; antihistamines, such as chlorpheniramine maleate; analgesics, such as acetaminophen; or antibacterials, such as cetyl pyridinium chloride and other ingredients and excipients required for effective delivery of the dosage form.
10. A composition as claimed in claim 9 wherein the composition preferably comprising: (i) 1% to 99% by weight of nicotine base;
(ii) 1% to about 99% by weight of C1-C5 alkyl salicylate; and any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI (60mg); antitussives, such as dextromethorphan (20mg); antihistamines, such as chlorpheniramine maleate (24gm); analgesics, such as acetaminophen (lOOOmg); or antibacterials, such as cetyl pyridinium chloride (0.05 by weight of the composition) and other ingredients and excipients required for effective delivery of the dosage form.
11. A composition as claimed in claim 10 preferably comprising:
(i) 5% to 10% by weight nicotine base, and (ii) 10% to 25% by weight alkyl salicylate.
12. A composition as claimed in claims 9, 10 or 11 wherein the alkyl salicylate is selected from the group consisting of methyl salicylate, ethyl salicylate, amyl salicylate, and mixtures thereof.
13. A composition according to claim 12 wherein the alkyl salicylate is methyl salicylate.
14. A composition according to claim 11 wherein the weight ratios of (i):(ii) is about 5:1 to about 1:20.
15. A composition according to claim 11 or 14 wherein the weight ratio of (i):(ii) is about 1: 1 to about 1:5.
16. A composition according to claim 9, 10 or 11 further comprising 2% to 93% by weight aromatic compounds.
17. A composition according to claim 13 comprising 25% to 85% aromatic compounds.
18. A composition according to claim 16 or 17 wherein the aromatic compound is selected from the group consisting of camphor, menthol, sassafras oil, pine needle oil, eucalyptus oil, and mixtures thereof.
19. A composition in the form of a viscous semi-solid for use in delivering nicotine base in vapor form comprising:
(i) 2% to 10% by weight nicotine base; (ii) 5% to 20% by weight alkyl salicylate selected from the group consisting of methyl salicylate, ethyl salicylate, amyl salicylate, and mixtures thereof;
(iii) 5% to 30% by weight aromatic compound; and (iv) 40% to 93% by weight petrolatum and any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI (60mg); antitussives, such as dextromethorphan (20mg); antihistamines, such as chlorpheniramine maleate (24gm); analgesics, such as acetaminophen (lOOOmg); or antibacterials, such as cetyl pyridinium chloride (0.05 by weight of the composition) and other ingredients and excipients required for effective delivery of the dosage form.
20. A composition for use in delivering nicotine base in vapor form comprising:
(i) 2% to 25% by weight nicotine base; (ii) 5% to 75% by weight C1-Cs alkyl salicylate selected from the group consisting of methyl salicylate, ethyl salicylate, amyl salicylate, and mixtures thereof;
(iii) 3% to 93% by weight aromatic compound; and (iv) 3% to 93% by weight of liquid vehicle selected from the group consisting of: (a) mineral oil;(b) ethanol, isopropyl alcohol, and a mixture thereof; (c) essential oil; and (d) mixtures thereof and further any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI (60mg); antitussives, such as dextromethorphan (20mg); antihistamines, such as chlorpheniramine maleate (24gm); analgesics, such as acetaminophen (lOOOmg); or antibacterials, such as cetyl pyridinium chloride (0.05 by weight of the composition).
21. A composition for use in delivering nicotine base in vapor form comprising:
(i) 1% to 2% by weight nicotine base; (ii) 1 % to 2% by weight alkyl salicylate selected from the group consisting of methyl salicylate, ethyl salicylate, amyl salicylate, and mixtures thereof; (iii) 0.1% to 5% by weight aromatic compound; and (iv) 90% to 96% by weight hardboiled candy composition along with and any one of the pharmaceutical agents listed below: decongestants, such as pseudonicotine HCI (60mg); antitussives, such as dextromethorphan (20mg); antihistamines, such as chlorpheniramine maleate (24gm); analgesics, such as acetaminophen (lOOOmg); or antibacterials, such as cetyl pyridinium chloride (0.05 by weight of the composition) and other ingredients and excipients required for effective delivery of the dosage form.
PCT/IN2007/000439 2006-09-25 2007-09-19 Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form Ceased WO2008062453A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1525/MUM/2006 2006-09-25
IN1525MU2006 2006-09-25

Publications (3)

Publication Number Publication Date
WO2008062453A2 WO2008062453A2 (en) 2008-05-29
WO2008062453A3 WO2008062453A3 (en) 2008-09-18
WO2008062453B1 true WO2008062453B1 (en) 2008-11-20

Family

ID=39367499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000439 Ceased WO2008062453A2 (en) 2006-09-25 2007-09-19 Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form

Country Status (1)

Country Link
WO (1) WO2008062453A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047779A2 (en) * 2007-06-20 2009-04-16 Nikki Nikhilesh Singh Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
BR122023020807A2 (en) * 2016-04-12 2023-12-12 Arturo Solis Herrera USE OF NICOTINUM ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF A CONDITION OF A NASAL OR PARANASAL MUCOUS MEMBRANE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73912A0 (en) * 1984-01-09 1985-03-31 Advanced Tobacco Prod Nicotine preparation
JP2004229627A (en) * 2003-01-29 2004-08-19 Yoshiaki Fujiyama Tobacco substitute inhaled through nose
DE10356925B4 (en) * 2003-12-05 2006-05-11 Lts Lohmann Therapie-Systeme Ag Inhaler for basic active pharmaceutical ingredients and process for its preparation

Also Published As

Publication number Publication date
WO2008062453A2 (en) 2008-05-29
WO2008062453A3 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
KR101170844B1 (en) Transmucosal drug delivery system
JP5524442B2 (en) Novel combination of anticholinergic and beta-mimetic for the treatment of respiratory diseases
JP4500045B2 (en) Composition for the treatment of the common cold
AU2002318211A1 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
JP2007507538A5 (en)
CA2452872A1 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
TW200407142A (en) New formulation and use thereof
MX2009009131A (en) Improvements in and relating to medicinal compositions.
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2344637A1 (en) .delta.9 tetrahydrocannabinol (.delta.9 thc) solution metered dose inhalers and methods of use
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
MX2012013380A (en) Liquid nasal spray containing low-dose naltrexone.
EP1515711A1 (en) Pharmaceutical composition
MXPA05009629A (en) Trospium containing compositions.
CA2469200A1 (en) Analgesic delivery systems and methods of use
Islam et al. Improved treatment of nicotine addiction and emerging pulmonary drug delivery
IE920484A1 (en) Pharmaceutical Formulations
US20100029771A1 (en) Treatment of addictive disorders
CA2483090A1 (en) Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions
CN113453665A (en) Naloxone formulations for sublingual and/or buccal administration
JP2008115167A (en) Suppressor for goblet cell hyperplasia of respiratory tract containing tranexamic acid
WO2008062453B1 (en) Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
TW201900215A (en) Composition and method for treating rheumatoid arthritis
MXPA06009094A (en) Controlled release formulations.
WO2010025505A1 (en) Analgesia by transmucosal administration

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07866710

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07866710

Country of ref document: EP

Kind code of ref document: A2